FACTOR XA

US Approved Rx (2013)

First approved in 2013

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 02:01:03 GMT 2025` Edited by `admin` on `Wed Apr 02 02:01:03 GMT 2025`
Protein Type	COAGULATION FACTOR
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	HYF6HN9XGQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FACTOR XA

Common Name

English

Factor x (stuart prower factor) [WHO-DD]

Preferred Name

English

STUART-PROWER FACTOR

Common Name

English

Code System Code Type Description

FDA UNII

HYF6HN9XGQ

Created by admin on Wed Apr 02 02:01:03 GMT 2025 , Edited by admin on Wed Apr 02 02:01:03 GMT 2025

PRIMARY

LACTMED

Factor Xa (recombinant), Inactivated

Created by admin on Wed Apr 02 02:01:03 GMT 2025 , Edited by admin on Wed Apr 02 02:01:03 GMT 2025

PRIMARY

From	To
1_181	1_209
1_156	1_170
1_108	2_132
1_27	1_43
1_7	1_12
2_17	2_22
2_50	2_61
2_55	2_70
2_72	2_81
2_89	2_100
2_96	2_109
2_111	2_124

Related Record Type Details


					K9GJ38KJ9F

YM-466 free base

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					S173RED00L

OTAMIXABAN

INHIBITOR -> TARGET

Amount:


					0LN50R4A7P

KVD-001

NON-INHIBITOR->OFF TARGET

Amount:


					74RWP7W0J9

BETRIXABAN

INHIBITOR -> TARGET


					J177FOW5JL

FONDAPARINUX

INHIBITOR -> TARGET

Amount:


					H5XZ7LKC6C

R-1663

INHIBITOR -> TARGET

Qualification:

Ki

Amount:


					5FCH6YDY7Z

ERIBAXABAN

INHIBITOR -> TARGET

Amount:


					TSA990HP1K

LY-517717

INHIBITOR -> TARGET

Comments:

Exhibits 1000-fold greater selectivity relative to inhibition of other serine proteases.

Qualification:

Ki

Amount:


					X5QRR6Z56Q

TANOGITRAN

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					KF322K101S

DAREXABAN

INHIBITOR -> TARGET


					6ADD3H8MFZ

IDRAPARINUX

INHIBITOR -> TARGET

Amount:


					U2R67KV65Q

CIRAPARANTAG

INHIBITOR -> TARGET


					9NDF7JZ4M3

Rivaroxaban

INHIBITOR -> TARGET


					3Z9Y7UWC1J

APIXABAN

INHIBITOR -> TARGET

Amount:


					Y3WB03966W

LETAXABAN

INHIBITOR -> TARGET

Amount:


					NDU3J18APO

EDOXABAN

INHIBITOR -> TARGET


					53FM6EUY9U

Segatroxaban

INHIBITOR -> TARGET

Amount:


					10NHF3008V

FIDEXABAN

INHIBITOR -> TARGET

Amount:


					415ZN8YW42

TIFACOGIN

INHIBITOR -> TARGET


					3K2509846L

RAZAXABAN

INHIBITOR -> TARGET

Amount:


					DQP38C562S

CT-001

ACTIVATOR -> TARGET

Amount:


					3TTT9ZD93F

Anpocogin

BINDER->LIGAND

Amount:


					H44R6RJT3S

IDRABIOTAPARINUX

INHIBITOR -> TARGET

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID SUBSTITUTION	[2_6] [2_7] [2_14] [2_16] [2_19] [2_20] [2_25] [2_26] [2_29] [2_31] [2_39] [2_40]		GLUTAMIC ACID		.GAMMA.-CARBOXYGLUTAMIC ACID	16FQV4RZKL
AMINO ACID SUBSTITUTION	[2_63]		ASPARTIC ACID		.BETA.-HYDROXY-L-ASPARTIC ACID, ERYTHRO-	GDV0MSK2SG

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL